All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type Gender, female Gender, male PD-L1 < 5% PD-L1 > 5% stage IIIb stage IIIc stage IV (metastatic) stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - (neo)adjuvant (NA), nivolumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 238, 2017 0.87 [0.66; 1.14]
0.87 [0.66 ; 1.14 ] CheckMate 238, 2017 1 0% 906 NA not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
0.73 [0.56 ; 0.96 ] CheckMate 238, 2017 1 0% 735 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
0.71 [0.59 ; 0.85 ] CheckMate 238, 2017 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
IMMUNED (N vs P ; all population), 2020 0.56 [0.33; 0.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.50 [1.26; 4.97]
0.92 [0.45 ; 1.89 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 86% 1,132 low not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
0.49 [0.20 ; 1.23 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
0.28 [0.21 ; 0.37 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to death (grade 5)detailed results IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.45 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 217 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
IMMUNED (N vs P ; all population), 2020 3.57 [0.71; 18.07]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.29 [0.07 ; 1.26 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 87% 1,122 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
IMMUNED (N vs P ; all population), 2020 4.90 [0.55; 43.46]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.24 [0.05 ; 1.09 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 83% 1,123 low not evaluable SAE (any grade)detailed results IMMUNED (N vs P ; all population), 2020 1.27 [0.56; 2.87]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.27 [0.12; 0.59]
0.58 [0.13 ; 2.64 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 86% 217 low not evaluable SAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 2.51 [0.94; 6.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.29 [0.13; 0.63]
0.83 [0.10 ; 6.97 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 91% 218 low not evaluable STRAE (any grade)detailed results IMMUNED (N vs P ; all population), 2020 6.13 [1.29; 29.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.08; 0.41]
0.97 [0.03 ; 31.56 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 93% 217 low not evaluable STRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 19.34 [1.09; 342.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.21 [0.09; 0.52]
1.64 [0.02 ; 132.78 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 88% 218 low not evaluable TRAE (any grade)detailed results CheckMate 238, 2017 0.25 [0.15; 0.43]
IMMUNED (N vs P ; all population), 2020 4.29 [1.74; 10.57]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.20 [0.04; 0.96]
0.62 [0.08 ; 4.75 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 93% 1,123 low not evaluable TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.20 [0.14; 0.27]
IMMUNED (N vs P ; all population), 2020 5.85 [1.58; 21.65]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.15 [0.07; 0.34]
0.49 [0.10 ; 2.37 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 92% 1,123 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.93 [0.02; 47.58]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.52 [0.07 ; 4.17 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,122 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 238, 2017 0.12 [0.08; 0.17]
IMMUNED (N vs P ; all population), 2020 7.29 [0.86; 61.51]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.28 [0.06 ; 1.28 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 86% 1,122 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.09 [0.05; 0.15]
IMMUNED (N vs P ; all population), 2020 9.90 [0.53; 186.01]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.19 [0.04 ; 0.88 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 80% 1,123 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.02; 14.96]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.73 [0.08 ; 6.31 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.54 [0.13 ; 2.22 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Alopecia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Anaemia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4.04 [0.18; 91.59]
1.52 [0.30 ; 7.73 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.03; 2.24]
0.25 [0.03 ; 2.24 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
2.98 [0.27 ; 32.69 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
0.91 [0.02 ; 46.72 ] IMMUNED (N vs P ; all population), 2020 1 0% 107 NA not evaluable Chills TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Colitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.30 [0.03 ; 3.29 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Cough TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.94 [0.27 ; 13.89 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.15 [0.07; 0.34]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
0.35 [0.07 ; 1.69 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 40% 1,123 low not evaluable Dizziness TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dry skin TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.02; 1.61]
0.39 [0.05 ; 3.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 20% 218 low not evaluable Eye disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.59 [0.14 ; 2.54 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.40 [0.03 ; 4.62 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.11 [0.01; 0.89]
0.13 [0.04 ; 0.40 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 25% 1,123 low not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.40 [0.03 ; 4.62 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.14 [0.02; 1.15]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.28 [0.05 ; 1.50 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Hepatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.30 [0.06; 1.57]
0.74 [0.07 ; 7.82 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 49% 218 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.13 [0.03; 0.63]
0.22 [0.06 ; 0.77 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 50% 1,123 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 1.00 [0.06; 16.07]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.50 [0.08 ; 3.08 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.04; 0.81]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
0.46 [0.09 ; 2.47 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 25% 1,123 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.66 [0.11 ; 4.05 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.02; 0.44]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.38 [0.06 ; 2.20 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 65% 1,123 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.07; 0.48]
IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.05; 0.68]
0.31 [0.08 ; 1.18 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 57% 1,123 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.17; 4.70]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.50 [0.17 ; 1.45 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Leucopenia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.05 [0.00; 0.95]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.21 [0.03 ; 1.43 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
1.26 [0.14 ; 10.99 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 5.72 [0.28; 116.99]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6.17 [0.30; 126.14]
5.94 [0.70 ; 50.19 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Myalgia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.91 [0.17 ; 21.35 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
1.28 [0.15 ; 11.02 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Nervous system disorders TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 3.74 [0.16; 84.94]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.00 [0.18; 22.72]
2.53 [0.37 ; 17.24 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Neutropenia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.01; 1.82]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.32 [0.04 ; 2.41 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.33 [0.05 ; 2.28 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.35 [0.13; 0.98]
0.35 [0.13 ; 0.98 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.36 [0.05 ; 2.74 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
IMMUNED (N vs P ; all population), 2020 1.84 [0.06; 55.93]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.32 [0.03; 3.13]
0.22 [0.09 ; 0.52 ] CheckMate 238, 2017, IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 3 0% 1,123 low not evaluable Stomatitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.64 [0.05 ; 8.40 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Uveitis TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Vitiligo TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Vomiting TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable Weight decreased TRAE (grade 3-4)detailed results IMMUNED (N vs P ; all population), 2020 0.91 [0.02; 46.72]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.95 [0.06 ; 15.31 ] IMMUNED (N vs P ; all population), 2020, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 218 low not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-18 06:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 284,70,235
- treatments: 360,719,721,720
